US5719147A
(en)
*
|
1992-06-29 |
1998-02-17 |
Merck & Co., Inc. |
Morpholine and thiomorpholine tachykinin receptor antagonists
|
AU690682B2
(en)
*
|
1994-05-05 |
1998-04-30 |
Merck Sharp & Dohme Limited |
Morpholine derivatives and their use as antagonists of tachikinins
|
DE69521208T2
(de)
*
|
1994-08-15 |
2001-11-08 |
Merck Sharp & Dohme |
Morpholinderivate und ihre verwendung als therapeutische mittel
|
GB9417956D0
(en)
*
|
1994-09-02 |
1994-10-26 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9426104D0
(en)
*
|
1994-12-23 |
1995-02-22 |
Merck Sharp & Dohme |
Use of surfactants and emulsions
|
GB9505491D0
(en)
*
|
1995-03-18 |
1995-05-03 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9513972D0
(en)
*
|
1995-07-08 |
1995-09-06 |
Merck Sharp & Dohme |
Pharmaceutical compositions
|
GB9523244D0
(en)
*
|
1995-11-14 |
1996-01-17 |
Merck Sharp & Dohme |
Therapeutic agents
|
US5891875A
(en)
*
|
1996-05-20 |
1999-04-06 |
Eli Lilly And Company |
Morpholinyl tachykinin receptor antagonists
|
WO1998002158A1
(en)
*
|
1996-07-17 |
1998-01-22 |
Merck & Co., Inc. |
Alteration of circadian rhythmicity with a tachykinin antagonist
|
US6117855A
(en)
|
1996-10-07 |
2000-09-12 |
Merck Sharp & Dohme Ltd. |
Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
|
EP0942729B1
(de)
*
|
1996-12-02 |
2004-09-01 |
MERCK SHARP & DOHME LTD. |
Die verwendung von nk-1 rezeptor antagonisten für die behandlungen von stress störungen
|
ES2234039T3
(es)
*
|
1996-12-02 |
2005-06-16 |
MERCK SHARP & DOHME LTD. |
Uso de antagonistas del receptor nk-1 para tratar trastornos de depresion mayor.
|
CA2273856A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating bipolar disorders
|
EP0942735A1
(de)
*
|
1996-12-02 |
1999-09-22 |
MERCK SHARP & DOHME LTD. |
Die verwendung von nk-1 rezeptor antagonisten für die behandlung von schizophrenischen störungen
|
AU734860B2
(en)
*
|
1996-12-02 |
2001-06-21 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating cognitive disorders
|
JP2001504850A
(ja)
*
|
1996-12-02 |
2001-04-10 |
メルク シヤープ エンド ドーム リミテツド |
不安を伴う重抑鬱性障害を治療するためのnk−1受容体拮抗薬の使用
|
WO1998024439A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating severe anxiety disorders
|
US5977104A
(en)
*
|
1996-12-02 |
1999-11-02 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating bipolar disorders
|
US6114315A
(en)
*
|
1996-12-02 |
2000-09-05 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
|
AU731674B2
(en)
*
|
1996-12-02 |
2001-04-05 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating substance use disorders
|
US6613765B1
(en)
|
1996-12-02 |
2003-09-02 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating major depressive disorders
|
JP2001504851A
(ja)
*
|
1996-12-02 |
2001-04-10 |
メルク シヤープ エンド ドーム リミテツド |
性的機能不全の治療のためのnk−1受容体拮抗薬の使用
|
ATE282417T1
(de)
*
|
1996-12-02 |
2004-12-15 |
Merck Sharp & Dohme |
Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
|
US6100256A
(en)
*
|
1996-12-02 |
2000-08-08 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptors antagonists for treating schizophrenic disorders
|
GB9700555D0
(en)
*
|
1997-01-13 |
1997-03-05 |
Merck Sharp & Dohme |
Therapeutic agents
|
AU744261B2
(en)
*
|
1997-04-24 |
2002-02-21 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating eating disorders
|
AU738047B2
(en)
*
|
1997-08-04 |
2001-09-06 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating mania
|
AU737019B2
(en)
*
|
1997-08-04 |
2001-08-09 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating aggressive behaviour disorders
|
GB9716457D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9716463D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
US5972938A
(en)
|
1997-12-01 |
1999-10-26 |
Merck & Co., Inc. |
Method for treating or preventing psychoimmunological disorders
|
US6156749A
(en)
*
|
1997-12-01 |
2000-12-05 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating movement disorders
|
US6087348A
(en)
*
|
1997-12-01 |
2000-07-11 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating stress disorders
|
US6271230B1
(en)
|
1997-12-01 |
2001-08-07 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating cognitive disorders
|
GB9810092D0
(en)
*
|
1998-05-11 |
1998-07-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9812664D0
(en)
*
|
1998-06-11 |
1998-08-12 |
Merck Sharp & Dohme |
Therapeutic use
|
GB9812662D0
(en)
*
|
1998-06-11 |
1998-08-12 |
Merck Sharp & Dohme |
Therapeutic use
|
EP1085873A1
(de)
*
|
1998-06-11 |
2001-03-28 |
MERCK SHARP & DOHME LTD. |
Vewrwendung von nk-1 rezeptor antagonisten zur behandlung von psychiatrischen krankheiten
|
GB9812617D0
(en)
*
|
1998-06-11 |
1998-08-12 |
Merck Sharp & Dohme |
Therapeutic use
|
AU4279699A
(en)
*
|
1998-06-11 |
1999-12-30 |
Merck Sharp & Dohme Limited |
Use of a nk-1 receptor antagonist for treating psychiatric disorders
|
GB9813025D0
(en)
*
|
1998-06-16 |
1998-08-12 |
Merck Sharp & Dohme |
Chemical synthesis
|
GB9816897D0
(en)
*
|
1998-08-04 |
1998-09-30 |
Merck Sharp & Dohme |
Therapeutic use
|
AU1230000A
(en)
*
|
1998-10-30 |
2000-05-22 |
Merck & Co., Inc. |
Linear process for the preparation of a morpholine compound
|
CA2348526A1
(en)
*
|
1998-10-30 |
2000-05-11 |
Merck & Co., Inc. |
Process for the preparation of 2-(r)-(1- (r)-(3,5-bis (trifluoromethyl) phenyl)ethoxy) -4-((5-dimethylaminomethyl) -1,2,3-triazol -4-yl)methyl) -3-(s)-(4- fluorophenyl) morpholine
|
CN1134417C
(zh)
|
1999-02-24 |
2004-01-14 |
弗·哈夫曼-拉罗切有限公司 |
3-苯基吡啶衍生物及其作为nk-1受体拮抗剂的应用
|
YU59801A
(sh)
|
1999-02-24 |
2005-07-19 |
F. Hoffmann-La Roche Ag. |
Fenil- i piridinil-derivati
|
DK1035115T3
(da)
|
1999-02-24 |
2005-01-24 |
Hoffmann La Roche |
4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister
|
US6291465B1
(en)
|
1999-03-09 |
2001-09-18 |
Hoffmann-La Roche Inc. |
Biphenyl derivatives
|
JO2308B1
(en)
|
1999-05-31 |
2005-09-12 |
اف. هوفمان- لاروش أيه جي |
Derivatives of phenylpyrmidine
|
TW550258B
(en)
|
1999-05-31 |
2003-09-01 |
Hoffmann La Roche |
4-phenyl-pyrimidine derivatives
|
JP2003513095A
(ja)
|
1999-10-29 |
2003-04-08 |
メルク エンド カムパニー インコーポレーテッド |
タキキニン受容体アンタゴニストの多形
|
PT1103545E
(pt)
*
|
1999-11-29 |
2004-03-31 |
Hoffmann La Roche |
2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida
|
US6452001B2
(en)
|
2000-05-25 |
2002-09-17 |
Hoffmann-La Roche Inc. |
Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation
|
US6482829B2
(en)
|
2000-06-08 |
2002-11-19 |
Hoffmann-La Roche Inc. |
Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
|
AR030284A1
(es)
|
2000-06-08 |
2003-08-20 |
Merck & Co Inc |
Proceso para la sintesis de (2r, 2-alfa-r,3a) -2-[1-(3,5-bis(trifluorometil) fenil) etoxi]-3-(4-fluorofenil)-1,4-oxazina; dicho compuesto y sus formas polimorficas
|
AU2001269749A1
(en)
*
|
2000-06-09 |
2001-12-24 |
Merck And Co., Inc. |
Trans-glycosidation process for the synthesis of (2r, 2-alpha-r, 3a)-2-(1-(3,5-bis(trifluoromethyl)phenyl) ethoxy)-3-(4-fluorophenyl)-1,4-oxazine
|
DE60134749D1
(de)
|
2000-07-14 |
2008-08-21 |
Hoffmann La Roche |
N-oxide als nk1-rezeptorantagonistenprodrugs von 4-phenylpyridinderivaten
|
TWI287003B
(en)
|
2000-07-24 |
2007-09-21 |
Hoffmann La Roche |
4-phenyl-pyridine derivatives
|
TWI259180B
(en)
|
2000-08-08 |
2006-08-01 |
Hoffmann La Roche |
4-Phenyl-pyridine derivatives
|
GB0020721D0
(en)
*
|
2000-08-22 |
2000-10-11 |
Merck Sharp & Dohme |
Therapeutic agents
|
YU39503A
(sh)
|
2000-11-22 |
2006-05-25 |
F. Hoffmann-La Roche Ag. |
Derivati pirimidina
|
US6642226B2
(en)
|
2001-02-06 |
2003-11-04 |
Hoffman-La Roche Inc. |
Substituted phenyl-piperidine methanone compounds
|
US6849624B2
(en)
|
2001-07-31 |
2005-02-01 |
Hoffmann-La Roche Inc. |
Aromatic and heteroaromatic substituted amides
|
US6638981B2
(en)
|
2001-08-17 |
2003-10-28 |
Epicept Corporation |
Topical compositions and methods for treating pain
|
CN100562320C
(zh)
|
2003-01-31 |
2009-11-25 |
弗·哈夫曼-拉罗切有限公司 |
2-(3,5-二-三氟甲基-苯基)-N-[6-(1,1-二氧代-1λ6-硫代吗啉-4-基)-4-(4-氟-2-甲基-苯基)-吡啶-3-基]-N-甲基-异丁酰胺的新晶体变体
|
NZ544244A
(en)
|
2003-07-03 |
2008-10-31 |
Hoffmann La Roche |
Dual NK1/NK3 antagonists for treating schizophrenia
|
US7288658B2
(en)
|
2003-07-15 |
2007-10-30 |
Hoffmann-La Roche Inc. |
Process for preparation of pyridine derivatives
|
ES2246687B2
(es)
|
2004-02-11 |
2006-11-16 |
Miguel Muñoz Saez |
Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
|
KR101389246B1
(ko)
|
2004-07-15 |
2014-04-24 |
브리스톨-마이어스스퀴브컴파니 |
아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
|
RU2401125C2
(ru)
|
2004-12-27 |
2010-10-10 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Способ стабилизации лекарственного средства против деменции
|
CN101128429B
(zh)
|
2005-02-22 |
2012-03-21 |
弗·哈夫曼-拉罗切有限公司 |
Nk1拮抗物
|
DE602006005624D1
(de)
|
2005-03-23 |
2009-04-23 |
Hoffmann La Roche |
Metaboliten für nk-i-antagonisten zur emesis
|
US8362075B2
(en)
|
2005-05-17 |
2013-01-29 |
Merck Sharp & Dohme Corp. |
Cyclohexyl sulphones for treatment of cancer
|
KR101594898B1
(ko)
|
2005-07-15 |
2016-02-18 |
알바니 몰레큘라 리써치, 인크. |
아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
|
JP5523706B2
(ja)
*
|
2005-09-23 |
2014-06-18 |
エフ.ホフマン−ラ ロシュ アーゲー |
新規投薬配合物
|
JP4879988B2
(ja)
|
2005-09-29 |
2012-02-22 |
メルク・シャープ・エンド・ドーム・コーポレイション |
メラノコルチン−4受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
|
WO2007039883A2
(en)
*
|
2005-10-05 |
2007-04-12 |
Ranbaxy Laboratories Limited |
Process for preparation of aprepitant
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
EP2946778A1
(de)
|
2006-09-22 |
2015-11-25 |
Merck Sharp & Dohme Corp. |
Behandlungsverfahren mit verwendung von fettsäuresyntheseinhibitoren
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
GEP20115337B
(en)
|
2007-01-10 |
2011-11-25 |
St Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
EP2117538A1
(de)
|
2007-01-24 |
2009-11-18 |
Glaxo Group Limited |
Pharmazeutische zusammensetzungen mit 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
|
JP5319518B2
(ja)
|
2007-04-02 |
2013-10-16 |
Msd株式会社 |
インドールジオン誘導体
|
ATE475645T1
(de)
|
2007-04-20 |
2010-08-15 |
Hoffmann La Roche |
Pyrrolidinderivate als doppelte nk1/nk3- rezeptorenantagonisten
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
JP2010535733A
(ja)
|
2007-08-07 |
2010-11-25 |
エフ.ホフマン−ラ ロシュ アーゲー |
Nk3受容体アンタゴニストとしてのピロリジンアリールエーテル
|
WO2009104080A2
(en)
|
2008-02-20 |
2009-08-27 |
Targia Pharmaceuticals |
Cns pharmaceutical compositions and methods of use
|
EP2247185B1
(de)
|
2008-03-03 |
2014-04-16 |
Tiger Pharmatech |
Tyrosinkinase-hemmer
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
JP5739415B2
(ja)
|
2009-05-12 |
2015-06-24 |
ブリストル−マイヤーズ スクウィブ カンパニー |
(S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用
|
EA020553B1
(ru)
|
2009-05-12 |
2014-12-30 |
Олбани Молекьюлар Рисерч, Инк. |
7-([1,2,4]ТРИАЗОЛО[1,5-α]ПИРИДИН-6-ИЛ)-4-(3,4-ДИХЛОРФЕНИЛ)-1,2,3,4-ТЕТРАГИДРОИЗОХИНОЛИН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ И ПСИХИЧЕСКИХ РАССТРОЙСТВ
|
WO2010132437A1
(en)
|
2009-05-12 |
2010-11-18 |
Albany Molecular Research, Inc. |
Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
|
MX2012004377A
(es)
|
2009-10-14 |
2012-06-01 |
Merck Sharp & Dohme |
Piperidinas sustituidas que aumentan la actividad de p53 y sus usos.
|
US8487102B2
(en)
|
2010-04-20 |
2013-07-16 |
Hoffmann-La Roche Inc. |
Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
|
EP2584903B1
(de)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Neue heterozyklische verbindungen als erk-hemmer
|
EP2601293B1
(de)
|
2010-08-02 |
2017-12-06 |
Sirna Therapeutics, Inc. |
Rna-interferenz-vermittelte hemmung der catenin (cadherin-assoziiertes protein)-beta-1 (ctnnb1)- genexpression mittels kurzer interferierender nukleinsäuren (sina)
|
ES2376564B1
(es)
|
2010-08-12 |
2013-01-24 |
Manuel Vicente Salinas Martín |
Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer.
|
AU2011292261B2
(en)
|
2010-08-17 |
2015-05-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
|
EP2608669B1
(de)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
|
EP2613782B1
(de)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazolderivate als erk-hemmer
|
EP2615916B1
(de)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Kondensierte pyrazolderivate als neue erk-hemmer
|
EP3327125B1
(de)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US20140045832A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Insulin-Like Growth Factor-1 Receptor Inhibitors
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
WO2013087964A1
(es)
|
2011-12-13 |
2013-06-20 |
Servicio Andaluz De Salud |
Uso de agentes modificadores del ambiente peritumoral para el tratamiento del cáncer
|
EP3453762B1
(de)
|
2012-05-02 |
2021-04-21 |
Sirna Therapeutics, Inc. |
Sina-zusammensetzungen
|
MX2015004041A
(es)
|
2012-09-28 |
2015-07-06 |
Merck Sharp & Dohme |
Compuestos novedosos que son inhibidores de erk.
|
RU2660349C2
(ru)
|
2012-11-28 |
2018-07-05 |
Мерк Шарп И Доум Корп. |
Композиции и способы для лечения злокачественной опухоли
|
US8846657B2
(en)
|
2012-12-20 |
2014-09-30 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as HDM2 inhibitors
|
EP2951180B1
(de)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8-substituierte purine als hdm2-inhibitoren
|
ES2493693B1
(es)
|
2013-02-11 |
2015-07-07 |
Servicio Andaluz De Salud |
Método para predecir o pronosticar la respuesta de un sujeto humano que padece un cáncer al tratamiento con un antagonista del receptor NK1
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
ES2541870B1
(es)
|
2013-12-27 |
2016-05-12 |
Servicio Andaluz De Salud |
Uso de antagonistas no peptídicos de NK1 en una determinada dosis para el tratamiento del cáncer
|
JP2017502973A
(ja)
*
|
2013-12-30 |
2017-01-26 |
オンコプレフェント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
癌を予防する方法において使用するためのニューロキニン−1受容体アンタゴニスト
|
TW201613888A
(en)
|
2014-09-26 |
2016-04-16 |
Helsinn Healthcare Sa |
Crystalline forms of an NK-1 antagonist
|
US10005803B2
(en)
|
2015-10-06 |
2018-06-26 |
Helsinn Healthcare Sa |
Crystalline forms of fosnetupitant
|
DK3435980T3
(da)
|
2016-06-06 |
2020-02-24 |
Helsinn Healthcare Sa |
Fysiologisk afbalancerede injicerbare formuleringer af fosnetupitant
|
EP3706742B1
(de)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5-inhibitoren
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
US11993602B2
(en)
|
2018-08-07 |
2024-05-28 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|